“She felt like she was buying toilet paper during COVID; she’s going to take it home on the T [train] and she feels like she has to extra protect it.” — Jody Dushay, MD, of Beth Israel Deaconess Medical Center in Boston, about one of her patients who recently picked up a refill for a scarce GLP-1 agonist drug.
“We are all over it.” — CDC Director Mandy Cohen, MD, MPH, speaking of her agency’s and the U.S. Department of Agriculture’s work to protect the public from avian flu.
“The problem is that it doesn’t work at all. It’s 100% bogus.” — Andrew Kolodny, MD, an opioid policy expert at Brandeis University in Massachusetts, discussing the AdvertD genetic test for opioid use disorder.
“They begin this kind of dance with that possibility and maintaining hope.” — Wendy Lichtenthal, PhD, of the University of Miami Sylvester Comprehensive Cancer Center, on the bereavement process starting before death.
“That’s going to be a real issue.” — David Reich, JD, senior fellow at the Center on Budget and Policy Priorities in Washington, on the pattern of flat funding for HHS.
“What we found was that people valued empathy, as measured by time spent with the doctor or the interpersonal manner of the provider, more than accessibility.” — Andrew Talal, MD, MPH, of the University at Buffalo, finding facilitated telemedicine led to better hepatitis C virus outcomes in an opioid treatment program.
“The simple question intervention doubled vaccine uptake and the messaging intervention nearly tripled vaccine uptake.” — Robert Rodriguez, MD, of the University of California San Francisco, discussing interventions that boosted flu vaccine uptake.
Please enable JavaScript to view the